Swedish neurotech startup Flow Neuroscience has secured FDA approval for the first brain stimulation device for home use in treating depression, a regulatory milestone that could reshape a mental health market facing a projected economic burden of $540 billion by 2030.

Ascletis Pharma has received investigational new drug (IND) clearance from the US Food and Drug Administration (FDA) to begin a 13-week Phase II study of its oral small molecule glucagon-like peptide (GLP)-1, ASC30, targeting participants with type 2 diabetes (T2D) mellitus.

The Food and Drug Administration has approved Novo Nordisk’s once-daily Wegovy pill, the first oral GLP-1 medicine for obesity in the United States. The full launch of the pill is expected in January.

Med Population Health, the leading digital health platform for GLP-1/GIP population health management, today announced it has been named a Novocare Recognized Care Provider delivering access to the newly FDA-approved Wegovy® pill,

The U.S. Food and Drug Administration (FDA) approved six new therapies in December 2025 for blood cancers, prostate cancer, lung cancer and supportive care. Approvals include both traditional and accelerated pathways and reflect results from recent clinical trials.

FDA approves first venous stent for IVC and iliofemoral veins, offering a new treatment for deep venous disease with proven 12-month patency.

The treatment for acquired thrombotic thrombocytopenic purpura, a rare blood disorder that causes blood clots in the small blood vessels, is the first drug approved for pediatric patients with aTTP. Cablivi was first approved by the FDA in 2019 to treat adults with the condition.

Edwards Lifesciences announced today that its Sapien M3 mitral valve replacement system received FDA approval for mitral regurgitation (MR).

Following Oral Wegovy Introduction, Consumer Analysis Examines Injectable vs Oral Semaglutide Pricing, Compounded Tirzepatide Access Through Direct Meds, and Three-Entity Telehealth Platform StructureHOUSTON,

The FDA has rejected Sanofi's application seeking approval of tolebrutinib to treat certain forms of MS in its present form.